EXHIBIT 4.9



 


THE
SECURITIES REPRESENTED BY THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AND HAVE BEEN ACQUIRED FOR INVESTMENT
AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED
WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE COMPANY THAT
SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933.


 


 


	Warrant
    No. CW-5	Number
    of Shares: 51,100
	Date of Issuance:
    February 4, 2010	(subject to adjustment)


 


BONE
BIOLOGICS, INC.


 


Common
Stock Purchase Warrant


 


Bone
Biologics, Inc., a California corporation (the “Company”), for value received, hereby certifies that Aragen
Bioscience, Inc., or its registered assigns (the “Registered Holder”), is entitled, subject to the terms
set forth below, to purchase from the Company, at any time after the date hereof and on or before the Expiration Date (as defined
in Section 5 below), up to 51,100 shares (as adjusted from time to time pursuant to the provisions of this Warrant) of common
stock of the Company (the “Common Stock”), at an exercise price of $0.44 per share. The shares issuable upon
exercise of this Warrant and the exercise price per share, as adjusted from time to time pursuant to the provisions of this Warrant,
are sometimes hereinafter referred to as the “Warrant Stock” and the “Exercise Price,” respectively.


 


This
Warrant is issued in consideration for the deferment of compensation for certain services previously rendered by Aragen Bioscience,
Inc. to the Company.


 


1.Exercise.


 


(a)Manner
of Exercise. This Warrant may be exercised by the Registered Holder, at any time and from time to time on or before the
Expiration Date, in whole or in part, by surrendering this Warrant, with the purchase/exercise form appended hereto as Exhibit
A duly executed by such Registered Holder or by such Registered Holder’s duly authorized attorney, at the principal
office of the Company, or at such other office or agency as the Company may designate, accompanied by payment in full of the aggregate
Exercise Price payable in respect of the number of shares of Warrant Stock purchased upon such exercise (the “Purchase
Price”), unless Holder exercises its net issue rights as set forth in Section 1(c) below. The Purchase Price may be
paid by cash, check, wire transfer or by the surrender of promissory notes or other instruments representing indebtedness of the
Company to the Registered Holder.


 


(b)Effective
Time of Exercise. Each exercise of this Warrant shall be deemed to have been effected immediately prior to the close of
business on the day on which this Warrant shall have been surrendered to the Company as provided in Section 1(a) above. At such
time, the person or persons in whose name or names any certificates for Warrant Stock shall be issuable upon such exercise as
provided in Section 1(d) below shall be deemed to have become the holder or holders of record of the Warrant Stock to be represented
by such certificates.


 






    	 



    	 



    

 


(c)Net
Issue Exercise.


 


(i)In
lieu of exercising this Warrant in the manner provided above in Section 1(a), the Registered Holder may elect to receive shares
equal to the value of this Warrant (or the portion thereof being canceled) by surrender of this Warrant at the principal office
of the Company together with notice of such election on the purchase/exercise form appended hereto as Exhibit A duly executed
by such Registered Holder or such Registered Holder’s duly authorized attorney, in which event the Company shall issue to
such Registered Holder a number of shares of Common Stock computed using the following formula:


 





	 	X
    =	Y
(A-B)
	 
	 	 	A	 


  


	Where	X
    =	The
                                         number of shares of Common Stock to be issued to the Registered Holder.

         

	 	Y
    =	The
                                         number of shares of Common Stock purchasable under this Warrant (at the date of such
                                         calculation).

         

	 	A
    =	The
                                         fair market value of one share of Common Stock (at the date of such calculation).

         

	 	B
    =	The
    Exercise Price (as adjusted to the date of such calculation).


 


(ii)For
purposes of this Section 1(c), the fair market value of one share of Common Stock on the date of calculation shall mean:


 


(A)if
the exercise is in connection with an initial public offering of the Company’s Common Stock, and if the Company’s
Registration Statement relating to such public offering has been declared effective by the Securities and Exchange Commission,
then the fair market value of Common Stock shall be the initial “Price to Public” per share specified in the final
prospectus with respect to the offering;


 


(B)if
this Warrant is exercised after, and not in connection with, the Company’s initial public offering, and if the Company’s
Common Stock is traded on a securities exchange or The Nasdaq Stock Market or actively traded over-the-counter:


 


(1)if
the Company’s Common Stock is traded on a securities exchange or The Nasdaq Stock Market, the fair market value shall be
deemed to be the average of the closing prices over a 30 day period ending three days before the date of calculation; or


 


(2)if
the Company’s Common Stock is actively traded over-the-counter, the fair market value shall be deemed to be the average
of the closing bid or sales price (whichever is applicable) over the 30 day period ending three days before the date of calculation;
or


 




    	-2-



    	 



    


 


(C)if
neither (A) nor (B) is applicable, the fair market value shall be at the highest price per share which the Company could obtain
on the date of calculation from a willing buyer (not a current employee or director) for shares of Common Stock sold by the Company,
from authorized but unissued shares, as determined in good faith by the Board of Directors, unless the Company is at such time
subject to an acquisition as described in Section 5(b) below, in which case the fair market value per share of Common Stock shall
be deemed to be the value of the consideration per share received by the holders of such stock pursuant to such acquisition.


 


(d)Delivery
to Registered Holder. As soon as practicable after the exercise of this Warrant in whole or in part, and in any event
within ten days thereafter, the Company at its expense will cause to be issued in the name of, and delivered to, the Registered
Holder, or as such Registered Holder (upon payment by such Registered Holder of any applicable transfer taxes) may direct:


 


(i)a
certificate or certificates for the number of shares of Warrant Stock to which such Registered Holder shall be entitled, and


 


(ii)in
case such exercise is in part only, a new warrant or warrants (dated the date hereof) of like tenor and with the same date, calling
in the aggregate on the face or faces thereof for the number of shares of Warrant Stock equal (without giving effect to any adjustment
thereof) to the number of such shares called for on the face of this Warrant minus the number of such shares purchased by the
Registered Holder upon such exercise as provided in Section 1(a) above (without giving effect to any adjustment thereof).


 


2.Adjustments.


 


(a)Stock
Splits and Dividends. If outstanding shares of the Company’s Common Stock shall be subdivided into a greater number
of shares or a dividend in Common Stock shall be paid in respect of Common Stock, the Exercise Price in effect immediately prior
to such subdivision or at the record date of such dividend shall simultaneously with the effectiveness of such subdivision or
immediately after the record date of such dividend be proportionately reduced. If outstanding shares of Common Stock shall be
combined into a smaller number of shares, the Exercise Price in effect immediately prior to such combination shall, simultaneously
with the effectiveness of such combination, be proportionately increased. When any adjustment is required to be made in the Exercise
Price, the number of shares of Warrant Stock purchasable upon the exercise of this Warrant shall be changed to the number determined
by dividing (i) an amount equal to the number of shares issuable upon the exercise of this Warrant immediately prior to such adjustment,
multiplied by the Exercise Price in effect immediately prior to such adjustment, by (ii) the Exercise Price in effect immediately
after such adjustment.


 


(b)Reclassification,
Etc. In case of any reclassification or change of the outstanding securities of the Company (or any other corporation
the stock or securities of which are at the time receivable upon the exercise of this Warrant) or any similar corporate reorganization
on or after the date hereof, then and in each such case the holder of this Warrant, upon the exercise hereof at any time after
the consummation of such reclassification, change, reorganization, merger or conveyance, shall be entitled to receive, in lieu
of the stock or other securities and property receivable upon the exercise hereof prior to such consummation, the stock or other
securities or property to which such holder would have been entitled upon such consummation if such holder had exercised this
Warrant immediately prior thereto, all subject to further adjustment as provided in Section 2(a); and in each such case, the terms
of this Section 2 shall be applicable to the shares of stock or other securities properly receivable upon the exercise of this
Warrant after such consummation.


 




    	-3-



    	 



    


  


(c)Adjustment
Certificate. When any adjustment is required to be made in the Warrant Stock or the Exercise Price pursuant to this Section
2, the Company shall promptly mail to the Registered Holder a certificate setting forth (i) a brief statement of the facts requiring
such adjustment, (ii) the Exercise Price after such adjustment and (iii) the kind and amount of stock or other securities or property
into which this Warrant shall be exercisable after such adjustment.


 


3.Transfers.


 


(a)Unregistered
Security. Each holder of this Warrant acknowledges that this Warrant and the Warrant Stock have not been registered under
the Securities Act of 1933, as amended (the “Securities Act”), and agrees not to sell, pledge, distribute,
offer for sale, transfer or otherwise dispose of this Warrant or any Warrant Stock issued upon its exercise in the absence of
(i) an effective registration statement under the Securities Act as to this Warrant or such Warrant Stock and registration or
qualification of this Warrant or such Warrant Stock under any applicable U.S. federal or state securities law then in effect or
(ii) an opinion of counsel, satisfactory to the Company, that such registration and qualification are not required. Each certificate
or other instrument for Warrant Stock issued upon the exercise of this Warrant shall bear a legend substantially to the foregoing
effect.


 


Transferability.
Subject to the provisions of Section 3(a) hereof, this Warrant and all rights hereunder are transferable, in whole or in part,
upon surrender of the Warrant with a properly executed assignment (in the form of Exhibit B hereto) at the principal office
of the Company.


 


(b)Warrant
Register. The Company will maintain a register containing the names and addresses of the Registered Holders of this Warrant.
Until any transfer of this Warrant is made in the warrant register, the Company may treat the Registered Holder of this Warrant
as the absolute owner hereof for all purposes; provided, however, that if this Warrant is properly assigned in blank, the Company
may (but shall not be required to) treat the bearer hereof as the absolute owner hereof for all purposes, notwithstanding any
notice to the contrary. Any Registered Holder may change such Registered Holder’s address as shown on the warrant register
by written notice to the Company requesting such change.


 


4.No
Impairment. The Company will not, by amendment of its charter or through reorganization, consolidation, merger, dissolution,
sale of assets or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this
Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such action
as may be necessary or appropriate in order to protect the rights of the holder of this Warrant against impairment.


 




    	-4-



    	 



    


 


5.Representations
and Warranties of Holder. The Registered Holder hereby represents and warrants to the Company as follows:


 


(a)Purchase
Entirely for Own Account. The Registered Holder acknowledges that this Warrant is given to the Registered Holder in reliance
upon the Registered Holder’s representation to the Company, which by its acceptance of this Warrant the Registered Holder
hereby confirms, that the Warrant, and the Warrant Stock (collectively, the “Securities”) being acquired by
the Registered Holder are being acquired for investment for the Registered Holder’s own account, not as a nominee or agent,
and not with a view to the resale or distribution of any part thereof, and that the Registered Holder has no present intention
of selling, granting any participation in, or otherwise distributing the same. By executing this Warrant, the Registered Holder
further represents that the Registered Holder does not presently have any contract, undertaking, agreement or arrangement with
any person to sell, transfer or grant participations to such person or to any third person, with respect to any of the Securities.
The Registered Holder represents that it has full power and authority to execute this Warrant. The Registered Holder has not been
formed for the specific purpose of acquiring any of the Securities.


 


(b)Disclosure
of Information. The Registered Holder has had an opportunity to discuss the Company’s business, management, financial
affairs and the terms and conditions of the offering of the Securities with the Company’s management. The Registered Holder
understands that such discussions, as well as any written information issued by the Company, were intended to describe the aspects
of the Company’s business which it believes to be material.


 


(c)Restricted
Securities. The Registered Holder understands that the Securities have not been, and will not be, registered under the
Securities Act, by reason of a specific exemption from the registration provisions of the Securities Act which depends upon, among
other things, the bona fide nature of the investment intent and the accuracy of the Registered Holder’s representations
as expressed herein. The Registered Holder understands that the Securities are “restricted securities” under applicable
U.S. federal and state securities laws and that, pursuant to these laws, the Registered Holder must hold the Securities indefinitely
unless they are registered with the Securities and Exchange Commission and qualified by state authorities, or an exemption from
such registration and qualification requirements is available. The Registered Holder acknowledges that the Company has no obligation
to register or qualify the Securities for resale. The Registered Holder further acknowledges that if an exemption from registration
or qualification is available, it may be conditioned on various requirements including, but not limited to, the time and manner
of sale, the holding period for the Securities, and on requirements relating to the Company which are outside of the Registered
Holder’s control, and which the Company is under no obligation and may not be able to satisfy.


 




    	-5-



    	 



    





 


(d)No
Public Market. The Registered Holder understands that no public market now exists for any of the securities issued by
the Company, that the Company has made no assurances that a public market will ever exist for the Securities.


 


(e)Legends.
The Registered Holder understands that the Securities, and any securities issued in respect of or exchange for the Securities,
may bear one or all of the following legends:


 


(i)“THE
SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AND HAVE BEEN ACQUIRED FOR
INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE
EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE COMPANY
THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933.”


 


(ii)Any
legend required by the Blue Sky laws of any state to the extent such laws are applicable to the shares represented by the certificate
so legended.


 


(f)Accredited
Investor. The Registered Holder is either an accredited investor as defined in Rule 501(a) of Regulation D promulgated
under the Securities Act or has such knowledge and experience (or is relying on a purchaser representative who has such knowledge
and experience) in financial and business matters that the Registered Holder is capable of evaluating the merits and risks of
acquiring the Securities.


 


6.Termination.
This Warrant (and the right to purchase securities upon exercise hereof) shall terminate upon the earliest to occur of the following
(the “Expiration Date”): (a) February 4, 2020, (b) the sale, conveyance or disposal of all or substantially
all of the Company’s property or business or the Company’s merger with or into or consolidation with any other corporation
(other than a wholly-owned subsidiary of the Company) or any other transaction or series of related transactions in which more
than 50% of the voting power of the Company is disposed of, provided that this Section 5(b) shall not apply to a merger
effected exclusively for the purpose of changing the domicile of the Company or to an equity financing in which the Company is
the surviving corporation, or (c) the closing of a firm commitment underwritten public offering pursuant to a registration statement
under the Securities Act.


 


7.Reservation
of Stock. The Company will at all times reserve and keep available, solely for the issuance and delivery upon the exercise
of this Warrant, such shares of Warrant Stock and other stock, securities and property, as from time to time shall be issuable
upon the exercise of this Warrant.


 


8.Exchange
of Warrants. Upon the surrender by the Registered Holder of any Warrant or Warrants, properly endorsed, to the Company
at the principal office of the Company, the Company will, subject to the provisions of Section 3 hereof, issue and deliver to
or upon the order of such Registered Holder, at the Company’s expense, a new Warrant or Warrants of like tenor, in the name
of such Registered Holder or as such Registered Holder (upon payment by such Registered Holder of any applicable transfer taxes)
may direct, calling in the aggregate on the face or faces thereof for the number of shares of Common Stock called for on the face
or faces of the Warrant or Warrants so surrendered.


 




    	-6-



    	 



    


 


9.Replacement
of Warrants. Upon receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation
of this Warrant and (in the case of loss, theft or destruction) upon delivery of an indemnity agreement (with surety if reasonably
required) in an amount reasonably satisfactory to the Company, or (in the case of mutilation) upon surrender and cancellation
of this Warrant, the Company will issue, in lieu thereof, a new Warrant of like tenor.


 


10.No
Rights as Stockholder. Until the exercise of this Warrant, the Registered Holder of this Warrant shall not have or exercise
any rights by virtue hereof as a stockholder of the Company.


 


11.No
Fractional Shares. No fractional shares of Common Stock will be issued in connection with any exercise hereunder. In lieu
of any fractional shares which would otherwise be issuable, the Company shall pay cash equal to the product of such fraction multiplied
by the fair market value of one share of Common Stock on the date of exercise, as determined in good faith by the Company’s
Board of Directors.


 


12.Amendment
or Waiver. Any term of this Warrant may be amended or waived only by an instrument in writing signed by the party against
which enforcement of the amendment or waiver is sought.


 


13.Headings.
The headings in this Warrant are used for convenience only and are not to be considered in construing or interpreting any provision
of this Warrant.


 


14.Governing
Law. This Warrant shall be governed, construed and interpreted in accordance with the laws of the State of California,
without giving effect to principles of conflicts of law.


 


15.Successors
and Assigns. Unless otherwise provided in this Warrant, the terms and conditions of this Warrant shall inure to the benefit
of and be binding upon the permitted successors and assigns of the parties. Nothing in this Warrant, express or implied, is intended
to confer upon any party other than the parties hereto or their respective successors and assigns any rights, remedies, obligations,
or liabilities under or by reason of this Warrant, except as expressly provided in this Warrant.


 


16.Counterparts.
This Warrant may be executed in two or more counterparts, each of which shall be deemed an original and all of which together
shall constitute one instrument.


 


17.Severability.
If one or more provisions of this Warrant are held to be unenforceable under applicable law, such provision shall be excluded
from this Warrant, the balance of this Warrant shall be interpreted as if such provision were so excluded and shall be enforceable
in accordance with its terms.


 




    	-7-



    	 



    


 


18.Delays
or Omissions. No delay or omission to exercise any right, power or remedy accruing to any party under this Warrant, upon
any breach or default of any other party under this Warrant, shall impair any such right, power or remedy of such non-breaching
or non- defaulting party nor shall it be construed to be a waiver of any such breach or default, or an acquiescence therein, or
of or in any similar breach or default thereafter occurring; nor shall any waiver of any single breach or default be deemed a
waiver of any other breach or default theretofore or thereafter occurring. Any waiver, permit, consent or approval of any kind
or character on the part of any party of any breach or default under this Warrant, or any waiver on the part of any party of any
provisions or conditions of this Warrant, must be in writing and shall be effective only to the extent specifically set forth
in such writing. All remedies, either under this Warrant or by law or otherwise afforded to any party, shall be cumulative and
not alternative.


 


19.Notices.
Unless otherwise provided herein, any notice required or permitted by this Warrant shall be in writing and shall be deemed sufficient
upon delivery, when delivered personally or by overnight courier or sent by facsimile, or 48 hours after being deposited in the
U.S. mail, as certified or registered mail, with postage prepaid, addressed to the party to be notified at such party’s
address as set forth on the signature page, or as subsequently modified by written notice.


 




    	-8-



    	 



    


 


18.Lock-Up
Agreement. In connection with the initial public offering of the Company’s securities and upon request of the Company
or the underwriters managing such offering of the Company’s securities, Registered Holder agrees not to sell, make any short
sale of loan grant any option for the purchase of, or otherwise dispose of any securities of the Company (other than those included
in the registration) without the prior written consent of the Company or such underwriters, as the case may be, for such period
of time (not to exceed 180 days but subject to such extensions as may be required by the underwriters in order to publish research
reports while complying with Rule 2711 of the Financial Industry Regulatory Authority Inc.) from the effective date of such registration
as may be requested by the Company or such managing underwriters and to execute an agreement reflecting the foregoing as may be
requested by the underwriters at the time of the Company’s initial public offering.


 


	 	BONE BIOLOGICS, INC.
	 	 	 
	 	By:	/s/
    Bruce A. Hazuka
	 	 	 
	 	Address: 	100
    Rancho Road
	 	 	Suite
    7 - #231
	 	 	Thousand
    Oaks, CA 91362
	 	 	 
	 	Facsimile
Number: 805-496-8937
	 	 
	 	Aragen Bioscience, Inc.



 


	 	By:	/s/ William
    R. Singley
	 	Print Name: William R. Singley
	 	Title:	President
    & CEO
	 	Address:	380
    Woodview Avenue
	 	 	Morgan
    Hill CA 95037


  




    	-9-



    	 



    


 


EXHIBIT
A


 


PURCHASE/EXERCISE
FORM


 


	To:	Bone
    Biologics, Inc	Dated:


 


The
undersigned, pursuant to the provisions set forth in the attached Warrant No. CW-5, hereby irrevocably elects to (a) purchase
_______ shares of the Common Stock covered by such Warrant and herewith makes payment of $ _____________, representing the full
purchase price for such shares at the price per share provided for in such Warrant, or (b) exercise such Warrant for _______ shares
purchasable under the Warrant pursuant to the Net Issue Exercise provisions of Section 1(c) of such Warrant.


 


The
undersigned acknowledges that it has reviewed the representations and warranties contained in Section 3 of the Agreement (as defined
in the Warrant) and by its signature below hereby makes such representations and warranties to the Company. Defined terms contained
in such representations and warranties shall have the meanings assigned to them in the Agreement.


 





	 	Signature:	 
	 	 	 
	 	Name
    (print):	 
	 	 	 
	 	Title (if applic.):	 
	 	 	 
	 	Company (if applic.):	 


  




    	 



    	 



    


 


EXHIBIT
B


 


ASSIGNMENT
FORM


 


FOR
VALUE RECEIVED, __________________________________________ hereby sells, assigns and transfers all of the rights of the undersigned
under the attached Warrant with respect to the number of shares of Common Stock covered thereby set forth below, to:


 





	Name
    of Assignee	Address/Fax
    Number	No,
    of Shares
	 	 	 
	 	 	 
	 	 	 


 





	Dated:	 	 	Signature:	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	Witness:	 


 






    	 



    	 



    

  







BONE
BIOLOGICS, INC.


 


AMENDMENT
NO. 1 TO

WARRANTS TO PURCHASE COMMON STOCK


 


This
Amendment No. 1 to
Warrants To Purchase
Common Stock (this “Amendment”)
is made as of September 17, 2014, by and between Bone Biologics,
Inc., a California corporation (the “Company”), and Aragen
Bioscience, Inc. holder
of certain warrants to purchase Common Stock of the Company (the “Holder”)


 


Recitals


 


WHEREAS,
pursuant to the deferral of payment the Company previously issued certain warrants to purchase Common Stock to the Holder (the
“Existing Warrants”);


 


WHEREAS,
the Company and the Holder desire to amend the Existing Warrants as provided herein;


 


WHEREAS,
pursuant to Section 12 of each of the Existing Warrants, any term of such Existing Warrants may be amended by the written consent
of the Company and the Holder (as defined in the Existing Warrants);


 


WHEREAS,
the undersigned Holder desires to amend the Existing Warrant as provided below.


 


NOW,
THEREFORE, in consideration of the mutual agreements, covenants and considerations contained herein, the Company and the undersigned
Holder hereby agree to amend the Existing Warrants as follows:


 


1.The
sixth paragraph of the Existing warrant is hereby amended and restated in its entirety as set forth below:


 


This
Warrant (and the right to purchase Warrant Stock upon exercise hereof) shall terminate upon the earliest to occur of the following
(the “Expiration Date”): (a) February 4, 2020, (b) the sale, conveyance or disposal of all or substantially all of
the Company’s property or business or the Company’s merger with or into or consolidation with any other corporation
(other than a wholly-owned subsidiary of the Company) or any other transaction or series of related transactions in which more
than 50% of the voting power of the Company is disposed of (each a “Significant Transaction”), provided that this
Section 6(b) shall not apply to a merger effected exclusively for the purpose of changing the domicile of the Company or to an
equity financing in which the Company is the surviving corporation, or (c) the closing of a firm commitment underwritten public
offering pursuant to a registration statement under the Securities Act. In the event of a Significant Transaction, the Registered
Holder shall thereafter be entitled to receive a warrant to purchase the kind and amount of shares of stock and other securities
and property (including cash) which the Registered Holder would have been entitled to receive had this Warrant been exercised
immediately prior to the effective date of such Significant Transaction.


 






    	 



    	 



    

 


2.Except
as expressly modified by this Amendment, all of the terms and conditions of the Existing Warrants are reaffirmed and shall remain
in full force and effect. Other than as stated in this Amendment, this Amendment shall not operate as a waiver of any condition
or obligation imposed on the parties under the Existing Warrants.


 


3.In
the event of any conflict, inconsistency, or incongruity between any provision of this Amendment and any provision of the Existing
Warrants, the provisions of this Amendment shall govern and control.


 


4.This
Amendment and all acts and transactions pursuant hereto and the rights and obligations of the parties hereto shall be governed,
construed and interpreted in accordance with the laws of the State of California, without giving effect to principles of conflicts
of law.


 


5.This
Amendment may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall
constitute one and the same instrument.


 


[Signature
Page Follows]


 




    	 



    	 



    


 


In
Witness Whereof, the undersigned
have executed this Amendment No.
1 to Warrants to
Purchase Common Stock
as of the day and year first set forth above.


 


	 	COMPANY:
	 	 	 
	 	Bone
    Biologics, Inc.
	 	 
	 	By:	/s/ William
    Jay Treat
	 	Name:	William
    Jay Treat
	 	Title:	President
    & CTO


 


Signature
Page to Amendment No. 1 to Warrants to Purchase Common Stock


 




    	 



    	 



    


 


In
Witness Whereof, the undersigned
have executed this Amendment No.
1 to Warrants to
Purchase Common Stock
as of the day and year first set forth above.


 


	 	HOLDER:
	 	 	 
	 	Aragen Bioscience, Inc.
	 	 	 
	 	By:	
	 	Name:	
	 	Title:	


 


Signature
Page to Amendment No. 1 to Warrants to Purchase Common Stock